Press Release: Key Announcements & Updates

AB Science completed a private placement of 2.3 million euros on July 2, 2026, according to a report by Le Soleil. The biotechnology company intends to use these funds to support its ongoing research and development efforts in the field of precision medicine.

The capital raise follows the company’s strategic focus on developing targeted therapies for oncology. By securing this funding through a private placement, AB Science maintains its liquidity to advance clinical trials and laboratory operations without the immediate need for a public offering.

Private placements allow companies to raise capital by selling shares directly to a select group of investors, such as institutional investors or wealthy individuals, rather than through an open market. This method typically provides a faster route to funding for biotech firms facing high research costs.

The 2.3 million euro figure represents a targeted injection of capital. According to Le Soleil, the success of this placement ensures the company can meet its immediate financial obligations while continuing to iterate on its drug candidates.

AB Science operates within the competitive landscape of precision oncology, where the goal is to match the right drug to the right patient based on genetic biomarkers. This approach differs from traditional chemotherapy by attempting to reduce systemic toxicity and increase efficacy.

The timing of this funding is critical for the company’s pipeline. Biotech firms typically utilize these funds to bridge the gap between early-phase discovery and the more expensive late-stage clinical trials required for regulatory approval.

The company’s ability to attract private investment indicates a level of confidence from its backers in the viability of its current scientific approach. This funding allows AB Science to maintain its operational tempo in a sector characterized by high volatility and long development cycles.